Sales of antimigraine drugs on the Russian retail market (including the online channel with delivery to consumers and the new regions) reached RUB 4.6 billion in 2025 (at retail prices, including VAT), with over 7.5 million packages of such drugs sold over the year. According to the database "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, the growth rate compared to 2024 was 32.6% in monetary terms. Physical volumes increased by 3.3% in packages, and when calculated in minimum dosage units (MDU), growth was recorded at 7.8%. The average per capita consumption of migraine medications in 2025 amounted to RUB 30.3, or about RUB 2.5 per month. In January 2026, the upward trend in consumption continued; compared to January 2025, we recorded sales growth of +42% in rubles and +5% in packages, with per capita consumption reaching RUB 2.9.

The main volume of antimigraine drug sales is concentrated in Moscow, Moscow Oblast, and Saint Petersburg. Together, these three regions account for over 35% of the market's monetary value and about 24% of sales in physical terms. Moreover, all three leading regions demonstrate consumption growth rates above the Russian average; specifically, the demand growth rate in Saint Petersburg was 38.3% in rubles. Notably, both Moscow and Saint Petersburg are also characterized by the highest levels of per capita consumption. Each resident of Moscow spent about RUB 5.3 per month on antimigraine drugs last year, while in the northern capital, spending was comparable, at around RUB 5.2 per month. It is important to note that the list of top regions for per capita consumption of antimigraine drugs includes several federal subjects that are not in the top ten or even the top 20 in terms of absolute sales volume. For example, each resident of Kaliningrad Oblast spent about RUB 3.5 per month on these drugs in 2025.

The absolute leader, both in terms of monetary and physical sales volume in the category, is Sumatriptan from Teva Pharmaceutical, accounting for nearly 20% of the market's monetary value. In second place, with a 14.9% share, is the Russian drug Exenza from Pharmamed. It is also notable for demonstrating tremendous growth rates, with ruble sales increasing 2.7 times compared to 2024. Interestingly, this high dynamic has continued into the current year; in January 2026, Exenza even moved into the top spot in the ranking. Overall, domestic producers are well represented in the segment. The total monetary share of Russian companies' products in the category at the end of last year stood at 58.2%, and the physical share approached 70%. Kaporiza from Sotex can also boast notable success, with sales of the drug doubling in 2025. The absolute leader in terms of growth dynamics was Ajovy (Teva Pharmaceutical), with ruble sales volume increasing 3.1 times compared to 2024, capturing an 8.9% market share in 2025.